News and Information Related to Cancer. Read about Colon, Lung, Prostate, Skin and many other forms of Cancer.
A Member of the Healthscout Network
 Printer Friendly  Send to a Friend

High Hormone Level Linked to Cancer Death in Older Men

More study needed to see if IGF-1 readings can predict risk

WEDNESDAY, March 3 (HealthDay News) -- High levels of a hormone called insulin-like growth factor 1 (IGF-1) are associated with an increased risk of cancer death in older men, a new study has found.

The findings, published in the March issue of the Journal of Clinical Endocrinology & Metabolism, suggest that IGF-1 may prove a useful biomarker for predicting cancer risk.

Advertisement
Related Stories
 border=
FDA Sends Warning to E-Cigarette Distributors
2 Genes Have Possible Link to Deadly Ovarian Cancer
Heart Health Rises With Education in Rich Nations
Related Videos
 border=
Erectile Dysfunction Drugs Do More Than Arouse
Saving Kids' Eyes: Retinoblastoma
Herpes Kills Cancer
Related Slides
 border=
Prostate Cancer
Uterine Cancer
Lung Cancer
Related Encyclopedia
 border=
Adenocarcinoma of the Lung and Brain Metastases
Basal Cell Carcinoma
Bladder Cancer


IGF-1, which is similar in structure to insulin, is regulated by growth hormone. Levels of growth hormone and IGF-1 decline as men and women age and this decrease is believed to be linked to health problems associated with old age. In an attempt to counter this, some people take supplemental growth hormone to elevate levels of IGF-1, according to background information in an Endocrine Society news release about the study.

"This is the first population-based study to show an association of higher IGF-1 levels with increased risk of a cancer-related death in older men," study corresponding author Gail Laughlin, of the University of California, San Diego, said in the news release. "Although the design of this study does not explicitly show that the higher IGF-1 levels caused the cancer death, it does encourage more study as well as a re-examination of the use of IGF-1 enhancing therapies as an anti-aging strategy."

The study included 633 men, aged 50 and older, whose IGF-1 levels were measured between 1988 and 1991. During 18 years of follow-up, men whose IGF-1 levels were above 100 nanograms per milliliter at the start of the study were nearly twice as likely to die of cancer as those with lower levels of the hormone.

"In this study, the increased risk of cancer death for older men with high levels of IGF-1 was not explained by differences in age, body size, lifestyle or cancer history," lead author Jacqueline Major said in the news release. "If these results are confirmed in other populations, these findings suggest that serum IGF-1 may have potential importance as a biomarker for prognostic testing."

More information

The U.S. National Cancer Institute has more about cancer risk factors.

-- Robert Preidt

SOURCE: The Endocrine Society, news release, March 1, 2010

Copyright © 2010 HealthDay. All rights reserved.
Last updated 3/3/2010



Disclaimer: The information provided on this website is for educational purposes only and does not serve as a replacement for care provided by your own personal health care team. This website does not render or provide medical advice, and no individual should make any medical decisions or change their health behavior based on information provided here. All pertinent content provided on this website should be discussed with your personal physician to evaluate whether it has any relevance to or impact on your specific condition. Reliance on any information provided by this website is solely at your own risk.


Sep 9, 2010
Home
Search
Powered By HealthLine
Patient Guide
News
Health Videos
Health Encyclopedia
Health News Archive
Affiliate Information
HealthScout Network
Contact Us
Newsletters
Privacy Policy
Terms of Use

We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service  

To find more information on specific conditions, please visit our partner sites: